The Dow Jones and S&P 500 held onto gains. Nvidia sank below a moving average while medical test stocks breaks out.

Investing.com -- Shares of MaxLinear (NASDAQ: MXL) plummeted 22% following the release of the company's fourth-quarter earnings and forward guidance, which fell short of investor expectations.

In a report released today, David Williams from Benchmark Co. reiterated a Buy rating on Maxlinear (MXL – Research Report), with a price target ...

David Williams, an analyst from Benchmark Co., reiterated the Buy rating on Maxlinear (MXL – Research Report). The associated price target ...

Greetings, and welcome to the MaxLinear fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.7, along with a high estimate of $28.00 and a low estimate of $14.00. This upward trend ...

CEO Kishore Seendripu highlighted that Q4 2024 results surpassed guidance midpoint with $92.2 million in revenue and a non-GAAP gross margin of 59.1%. He emphasized ongoing strength in customer order ...

MaxLinear, Inc. (Nasdaq: MXL), a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated ...

MaxLinear (MXL) delivered earnings and revenue surprises of 30.77% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — MaxLinear Inc. (MXL) on Wednesday reported a loss of $57.8 million in its fourth quarter. The Carlsbad, California-based company said it had a loss of ...

MaxLinear beat estimated earnings by 31.0%, reporting an EPS of $-0.09 versus an estimate of $-0.13. Revenue was down $33.19 million from the same period last year. During the previous quarter, the ...